Translate page

Perspectives from Professor Jorge Cortes, MD

MD Anderson Cancer Center
University of Texas, Houston, USA

  • Different aspects on treatment discontinuation including 2nd treatment discontinuation and QoL assessment
  • Presentation of a new tyrosine kinase inhibitor
  • Generics making it into practice
  • Predictive markers and their impact on patients outcome
  • Considerations for treatment discontinuation in clinical practice including AE management

{rscomments off}